1
|
Liu CG, Liao AJ. [Feature analysis of different neutrophil levels on the distribution of pathogens in bloodstream infection in patients with hematologic malignancy]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:857-860. [PMID: 38049340 PMCID: PMC10694080 DOI: 10.3760/cma.j.issn.0253-2727.2023.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Indexed: 12/06/2023]
Affiliation(s)
- C G Liu
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China
| | - A J Liao
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China
| |
Collapse
|
2
|
He K, An S, Liu F, Chen Y, Xiang G, Wang H. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma. Int J Biol Sci 2023; 19:4511-4524. [PMID: 37781033 PMCID: PMC10535702 DOI: 10.7150/ijbs.83862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Accepted: 08/01/2023] [Indexed: 10/03/2023] Open
Abstract
Although apatinib is a promising drug for the treatment of liver cancer, the underlying drug resistance mechanism is still unclear. Here, we constructed apatinib-resistant HepG2 cells. We then characterized the epigenomic, transcriptomic, and proteomic landscapes both in apatinib-resistant and non-resistant HepG2 cells. Differential expression, ATAC-seq, and proteomic data analyses were performed. We found that the cell cycle related protein RB1 may play an essential role in the process of apatinib resistant to hepatocarcinoma. Moreover, there were extensive variations at the transcriptome, epigenetic, and proteomic level. Finally, quantitative PCR (qPCR) and western blot analysis showed that expression level of RB1 in apatinib-resistant cell as well as the samples of patients in progressive disease were significantly lower than that in controls. Those results also showed that the RB1 pathway inhibitors CDK2-IN-73 and Palbociclib could relieve the resistance of apatinib resistant cells. Our results further enhance our understanding of the anti-tumorigenic and anti-angiogenic efficacy of apatinib in liver cancer and provide a novel perspective regarding apatinib resistance. Furthermore, we proved that CDKN2B inhibition of RB1 signaling promoted apatinib resistance in hepatocellular carcinoma. Those findings have greatly important biological significance for the resistance of apatinib and the treatment of liver cancer.
Collapse
Affiliation(s)
- Ke He
- Minimally Invasive Tumor Therapies Center, Guangdong Second Provincial General Hospital, Guangzhou 510317, China
- Department of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou 510317, China
- Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
| | - Sanqi An
- Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
| | - Fei Liu
- Minimally Invasive Tumor Therapies Center, Guangdong Second Provincial General Hospital, Guangzhou 510317, China
| | - Ye Chen
- Department of Critical Care Medicine, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Guoan Xiang
- Department of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou 510317, China
| | - Haihe Wang
- Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
| |
Collapse
|
3
|
Huang XL, Wu SH, Shi PF, Xu LH, Chen C, Xie YP, Gao DQ, Chen K, Tan JF, Liu LR, Xu Y, Yang F, Yu MX, Wang SY, Qian SX. [Active screening of intestinal carbapenem-resistant Enterobacteriaceae in high-risk patients admitted to the hematology wards and its effect evaluation]. Zhonghua Xue Ye Xue Za Zhi 2021; 41:932-936. [PMID: 33333697 PMCID: PMC7767815 DOI: 10.3760/cma.j.issn.0253-2727.2020.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
目的 观察血液科肠道碳青霉烯类耐药的肠杆菌科细菌(CRE)主动筛查患者CRE定植、感染的特征,并评价主动筛查结合加强干预在血液科患者CRE感染预防控制中的效果。 方法 以2017年3月至2019年12月血液内科接受化疗或免疫抑制治疗且预期会出现粒细胞缺乏(粒缺)的患者为研究对象,进行至少3个时间点(治疗前、治疗后粒缺期、粒缺伴发热期)的肠道CRE筛查,以2016年12月至2017年2月血液内科未开展肠道CRE主动筛查的、接受化疗或免疫抑制治疗的115例患者为历史对照组,两组患者均进行CRE感染实时监测,CRE筛查阳性者均采取接触隔离措施,CRE筛查阳性者出现发热或者感染症状时启动针对CRE联合抗生素治疗。 结果 主动筛查患者CRE定植率为16.46%(66/401);病种分布上,以急性白血病定植率最高,为23.03%(26/113)。66例筛查阳性患者中,其中第1次筛查阳性患者为27例,占40.9%(27/66),第2次筛查阳性患者为15例,占22.7%(15/66),第3次及以后筛查阳性患者为24例,占36.4%(24/66)。CRE定植病原菌中耐碳青霉烯类肺炎克雷伯菌(CRKP)最多,占54.55%(36/66)。主动筛查患者CRE感染率(2.49%)及死亡率(50.00%)低于历史对照组的11.30%及69.23%;干预期间10例CRE血流感染患者病原菌种类与前期主动筛查病原菌完全相同,符合率为100.0%。 结论 血液科病房急性白血病患者CRE定植率最高,CRKP是CRE定植、感染的主要病原菌,提高筛查频率可以显著提高筛查阳性率,采取主动筛查并及早干预能有效降低血液科患者CRE发生率及死亡率,CRE筛查阳性病原菌与后续CRE感染病原菌符合率高。恶性血液病患者肠道CRE筛查可以对后期CRE血流感染起到预警以及优化抗菌药物使用的作用。
Collapse
Affiliation(s)
- X L Huang
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - S H Wu
- Department of Microbiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - P F Shi
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - L H Xu
- Department of Microbiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - C Chen
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - Y P Xie
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - D Q Gao
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - K Chen
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - J F Tan
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - L R Liu
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - Y Xu
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - F Yang
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - M X Yu
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - S Y Wang
- Department of Hospital Infection Prevention and Control, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| | - S X Qian
- Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang 310006, China
| |
Collapse
|
4
|
Xu CH, Zhu GQ, Lin QS, Wang LL, Wang XX, Gong JY, Zhao NN, Yang DL, Feng SZ. [A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in adult patients with hematological disease during the period 2014-2018]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:643-8. [PMID: 32942817 DOI: 10.3760/cma.j.issn.0253-2727.2020.08.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
目的 探讨2014–2018年成人血液病患者发生血流感染的病原菌分布和耐药情况,为该类患者合理使用抗菌药物提供数据参考。 方法 回顾性分析2014年1月至2018年12月中国医学科学院血液病医院收治的血液病合并血流感染患者的临床资料、病原菌种类分布和药物敏感性数据。 结果 5年内共1 478例血液病患者发生1 935次血流感染,1 700例次(87.9%)发生在中性粒细胞缺乏期,14 d与30 d全因死亡率分别为5.5%和8.2%。52.7%的血流感染存在伴随症状,主要为呼吸道症状、肛周黏膜损伤及消化道症状,比例分别为12.4%、12.3%和9.1%。共分离出2 025株病原菌,革兰阴性菌1 551株(76.6%),主要为大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌;革兰阳性球菌423株(20.9%),主要为葡萄球菌属与草绿色链球菌;真菌51株(2.5%),以热带念珠菌为主。肠杆菌科细菌对哌拉西林/他唑巴坦、碳青霉烯类、阿米卡星耐药率<10%。其中肺炎克雷伯菌对头孢吡肟、哌拉西林/他唑巴坦、美罗培南耐药率呈逐年上升趋势。铜绿假单胞菌对哌拉西林/他唑巴坦、喹诺酮类、氨基糖苷类抗菌药物耐药率<5%,低于碳青霉烯类。共检出耐甲氧西林金黄色葡萄球菌11株,耐万古霉素肠球菌1株。 结论 成人血液病患者血流感染病原菌分布广泛,不同菌种耐药率差异较大,且部分菌种耐药呈上升趋势,应根据不同人群血流感染病原菌分布及耐药情况合理使用抗菌药物。
Collapse
|
5
|
Zheng YZ, Li J, Le SH, Zheng H, Hua XL, Chen ZS, Zheng L, Chen C, Hu JD. [Bacterial distribution and drug resistance of pathogens of blood stream infection in children with hematological malignancies after chemotherapy]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:235-237. [PMID: 30929393 PMCID: PMC7342547 DOI: 10.3760/cma.j.issn.0253-2727.2019.03.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Indexed: 11/26/2022]
Affiliation(s)
- Y Z Zheng
- Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fujian Medical University Union Hospital, Fuzhou 350001, China
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Xu CH, Su Y, Lyu YX, Tian ZY, Sun FJ, Lin QS, Wang C. [Perianal swabs surveillance cultures of Carbapenem-resistant Enterobacteriaceae(CRE) can be hints for CRE bloodstream infection in patients with hematological diseases]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:1021-1025. [PMID: 30612405 PMCID: PMC7348228 DOI: 10.3760/cma.j.issn.0253-2727.2018.12.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 探讨血液病患者肛周皮肤拭子细菌培养检出耐碳青霉烯类肠杆菌(CRE)对CRE血流感染的预警价值,寻找CRE血流感染的危险因素。 方法 对2016年1月至2017年12月进行肛周皮肤拭子细菌培养的血液病患者分离出CRE的耐药率、患者后期CRE血流感染发生情况及危险因素进行回顾性分析。 结果 2 914例血液病患者进行了肛周皮肤拭子细菌培养,74例检出CRE,其中后期发生CRE血流感染者13例(17.6%)。共分离出CRE 87株(相同患者相同部位去重),包括肺炎克雷伯菌31株、大肠埃希菌43株、阴沟肠杆菌8株、其他肠杆菌科细菌6株。分离出CRE菌株对哌拉西林/他唑巴坦、亚胺培南、美罗培南、阿米卡星、左氧氟沙星、替加环素的耐药率分别为91.9%、74.4%、98.8%、17.6%、74.4%和8.0%。13例发生CRE血流感染患者肛周皮肤拭子与血液中分离株对碳青霉烯类、氨基糖苷类、喹诺酮类及替加环素耐药程度一致率较高。粒细胞缺乏(粒缺)、存在消化道症状、肛周感染持续时间为肛周皮肤CRE阳性患者发生CRE血流感染的独立危险因素(OR值分别为1.10、1.13和1.23,P值分别为0.029、0.005、0.016)。 结论 对血液病患者进行肛周皮肤拭子细菌培养可为后期CRE血流感染提供预警,并可为其提供抗菌药物选择参考;粒缺、伴消化道症状以及肛周感染持续时间长可作为CRE血流感染患者早期识别因素。
Collapse
Affiliation(s)
- C H Xu
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | |
Collapse
|